Recent Updates
Recently added Catalysts
DFTX Positive Sentiment

Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights

Monday, November 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Definium Therapeutics reported its third quarter 2026 financial results, highlighting positive initial outcomes from its Phase 2a trial of DT402 in adults with autism spectrum disorder (ASD). The trial showed improvements, marking a significant step for the company. Financial results for the quarter ended September 30, 2026, were also disclosed.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive initial results from Phase 2a trial of DT402.
  • Improvements observed in adults with ASD.
  • Financial results indicate stability.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+130%
120-day peak, hindsight
Typical move
15.7%
average across 4 past catalysts
Cash runway
~59 mo
Low dilution risk
Lead asset
DT120
Phase 3 · Major Depressive Disorder

Full Press Release Details

NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (“Definium” or the “Company”) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended September 30, 2026, and recent highlights. The Company also reported positive initial results from its Phase 2a trial of DT402 in adults with ASD, with improvements obser

Frequently Asked Questions

What were the highlights of Definium's Q3 2026 report?

Definium reported positive results from its Phase 2a trial of DT402.

What is DT402 targeting?

DT402 is aimed at addressing autism spectrum disorder (ASD).

When did Definium report its financial results?

Definium reported its financial results for the quarter ended September 30, 2026.

What improvements were observed in the trial?

Improvements were noted in adults with ASD during the trial.

ShareAdd on Google
Tags: DFTX Definium Therapeutics DT402 ASD Q3 2026 biopharmaceutical
Last updated: Nov 9, 2026

Biotech snapshot

Cash runway
$1084M liquidity · $18M/mo burn
~59 mo
Low dilution risk
Lead asset
DT120Phase 3
Major Depressive Disorder →

Catalyst track record

+130%
best trade around DFTX's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for DFTX.

See every catalyst's timing & PoA →